Streetbeat News

SCNI

Scinai Immunotherapeutics Ltd.

https://www.scinai.com

Industry

Biotechnology

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Scinai Immunotherapeutics shares were halted on a circuit breaker due to a sharp decline but have since surged by 86%.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 1:42 pm

Scinai Immunotherapeutics shares have resumed trading after a temporary halt.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 1:40 pm

Scinai Immunotherapeutics shares were halted on a circuit breaker due to a significant upward movement, with the stock now up 95.8%.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 1:36 pm

Scinai Immunotherapeutics announced positive in-vivo preclinical study results for NanoAb, showing reduced levels of IL-17 isoforms in psoriatic skin tissue.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 11:04 am

Scinai Immunotherapeutics has received approval from Nasdaq to continue its listing, provided it meets the equity requirement by August 14, 2024.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2024 | 1:35 pm

Scinai Immunotherapeutics reported a Q1 EPS of $(0.001), an improvement from $(0.003) year-over-year.

Portfolio Pulse from Benzinga Newsdesk

July 02, 2024 | 12:17 pm

The article highlights the pre-market movements of 12 health care stocks on Friday. Notable gainers include DermTech (DMTK), Sarepta Therapeutics (SRPT), and Kintara Therapeutics (KTRA), while significant losers include Psyence Biomedical (PBM), CASI Pharmaceuticals (CASI), and Sonnet BioTherapeutics (SONN).

Portfolio Pulse from Benzinga Insights

June 21, 2024 | 12:08 pm

Quantum Corporation (NASDAQ:QMCO) shares fell 44.5% to $0.43 after reporting worse-than-expected FY24 financial results and issuing FY25 guidance below estimates. Other notable stock movements include Reliance Global Group (NASDAQ:RELI) jumping 350% after an acquisition update, and DermTech, Inc. (NASDAQ:DMTK) falling 58.4% after filing for Chapter 11 protection.

Portfolio Pulse from Avi Kapoor

June 18, 2024 | 5:39 pm

The article highlights significant intraday movements in health care stocks on Tuesday. Notable gainers include Mustang Bio, Sonoma Pharmaceuticals, Vaxart, Silk Road Medical, Kintara Therapeutics, and AtriCure. Major losers include DermTech, Zentalis Pharma, Anitra, Scinai Immunotherapeutics, Taysha Gene Therapies, and Autonomix Medical.

Portfolio Pulse from Benzinga Insights

June 18, 2024 | 4:31 pm

12 health care stocks experienced significant movements in Tuesday's pre-market session. Notable gainers include Sonoma Pharmaceuticals (SNOA), Qualigen Therapeutics (QLGN), and Mustang Bio (MBIO). Significant losers include DermTech (DMTK), Biolase (BIOL), and Zentalis Pharma (ZNTL).

Portfolio Pulse from Benzinga Insights

June 18, 2024 | 12:07 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.